Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer
18 Years
N/A
Both
Breast Cancer
Trial Information
Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer
OBJECTIVES:
Primary
- Determine the safety of telomerase: 540-548 peptide vaccine emulsified in Montanide
ISA-51 and sargramostim (GM-CSF) in patients with HLA-A2-expressing stage IV breast
cancer.
Secondary
- Compare the generation of human telomerase reverse transcriptase (hTERT)
peptide-specific vs cytomegalovirus peptide-specific cytotoxic T-lymphocyte (CTL)
immunity in patients treated with this regimen.
- Correlate the dose level of this regimen with the generation of hTERT-specific CTL
immunity and the development of hTERT-specific autoimmunity in these patients.
- Determine the tumor response in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of the telomerase: 540-548 peptide and CMV 495
peptide portions of the vaccine.
Patients receive telomerase: 540-548 peptide and CMV 495 peptide (as an immunological
control) vaccine emulsified in Montanide ISA-51 subcutaneously (SC) followed by sargramostim
(GM-CSF) SC on day 1 of weeks 1, 3, 5, 7, 11, 15, 19, and 27 (for a total of 8
vaccinations). Treatment continues in the absence of disease progression or unacceptable
toxicity.
Cohorts of 5-8 patients receive escalating doses of telomerase: 540-548 peptide and CMV 495
peptide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose
preceding that at which 2 of 5 or 2 of 8 patients experience dose-limiting toxicity. A total
of 12 patients receive treatment at the MTD.
Patients are followed within 30 days and then at 6 and 12 months.
PROJECTED ACCRUAL: A total of 5-28 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of stage IV breast cancer
- Failed at least 1 prior conventional therapy for metastatic disease
- Measurable or evaluable disease by clinical, radiographic, or laboratory assessment
- Measurable lesions must be at least 1 dimension
- At least 20 mm by conventional techniques OR at least 10 mm by spiral CT
scan
- The following are not considered measurable:
- Pleural effusion
- Bone lesions
- Tumor markers
- HLA-A2-expressing disease by human leukocyte antigen typing
- No CNS metastases by contrast CT scan and/or MRI
- No brain metastases within the past 4 years
- Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Not specified
Menopausal status
- Not specified
Performance status
- ECOG 0-1
Life expectancy
- More than 6 months
Hematopoietic
- WBC ≥ 3,000/mm^3
- Platelet count ≥ 75,000/mm^3
- Hemoglobin ≥ 10 g/dL
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT and AST ≤ 2.5 times ULN
- Hepatitis B negative
- Hepatitis C negative
Renal
- Creatinine ≤ 1.5 times ULN
Immunologic
- HIV negative
- Human T-cell lymphotrophic virus-1 negative
- No active infection
- No major autoimmune disorder that would preclude study participation
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after study
participation
- No alcohol abuse or illicit drug use within the past 12 months
- No clinically significant comorbid disease or other underlying condition that would
preclude study participation
- No significant psychiatric disorder that would preclude giving informed consent or
complying with study
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior allogeneic or autologous bone marrow or stem cell transplantation
- More than 30 days since prior hematopoietic growth factors
- More than 30 days since initiation of prior immunotherapy (e.g., trastuzumab
[Herceptin])
- Concurrent immunotherapy (e.g., trastuzumab) allowed provided regimen was initiated
more than 30 days before study entry, disease is stable or progressive, and patient
plans to continue immunotherapy for the duration of study participation
- No other concurrent hematopoietic growth factors
Chemotherapy
- More than 30 days since prior chemotherapy
- No concurrent chemotherapy
Endocrine therapy
- More than 30 days since prior glucocorticoids
- More than 30 days since initiation of prior hormonal therapy (e.g., tamoxifen,
anastrozole, or letrozole)
- Concurrent hormonal therapy (e.g., tamoxifen, anastrozole, or letrozole) allowed
provided regimen was initiated more than 30 days before study entry, disease is
stable or progressive, and patient plans to continue hormonal therapy for the
duration of study participation
- No concurrent glucocorticoids
Radiotherapy
- More than 30 days since prior radiotherapy
- No concurrent radiotherapy
Surgery
- Not specified
Other
- More than 14 days since prior anticoagulants (e.g., warfarin, heparin, or enoxaparin)
- Low-dose anticoagulants to maintain IV catheter patency allowed
- More than 30 days since prior immunosuppressive drugs
- More than 30 days since prior experimental therapy
- No concurrent immunosuppressive drugs
- No other concurrent investigational products
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Principal Investigator
Susan Domchek, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Abramson Cancer Center of the University of Pennsylvania
Authority:
United States: Federal Government
Study ID:
CDR0000354502
NCT ID:
NCT00079157
Start Date:
February 2004
Completion Date:
Related Keywords:
- Breast Cancer
- recurrent breast cancer
- stage IV breast cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania 19104-4283 |
